AUTHOR=Luo Yuxi , Ouyang Weiwei 

TITLE=Case Report: A rare case of ALK-KIF5B gene fusion benefited from treatment with lorlatinib

JOURNAL=Frontiers in Oncology

VOLUME=Volume 15 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1594072

DOI=10.3389/fonc.2025.1594072

ISSN=2234-943X

ABSTRACT=The anaplastic lymphoma kinase (ALK) gene encodes a transmembrane receptor tyrosine kinase. Most mutations in ALK gene result from translocations with other genes, forming fusion oncogenes. To date, 21 different genes have been identified as ALK fusion partners, each activating distinct signaling pathways that influence cancer cell proliferation, invasiveness, and tumorigenicity. ALK tyrosine kinase inhibitors (ALK-TKIs) have demonstrated significant efficacy in ALK-positive non-small cell lung cancer (NSCLC) and are widely utilized as first-line therapy. Lorlatinib, a third-generation ALK inhibitor, is effective in both treatment-naïve and previously treated patients with advanced NSCLC, exhibiting strong systemic and intracranial antitumor activity. This report presented a case of lung adenocarcinoma with 51 genetic variants, including a rare fusion variant: exon 15 of KIF5B fused to exon 20 of ALK, KIF5B-ALK (K15:A20). Following lorlatinib treatment, partial remission was achieved, and disease stability was maintained for an extended period, suggesting a favorable response to therapy. This case highlighted the potential sensitivity of the KIF5B-ALK (K15:A20) fusion to lorlatinib and the need for further investigation into lorlatinib’s efficacy across different KIF5B-ALK fusion variants. Additionally, other fusion types and treatment options for KIF5B-ALK fusions with varying breakpoints were discussed.